Dr Hafez on the Design of the FeDeriCa Trial in HER2+ Early Breast Cancer

Maria Hafez, MD, discusses the design of, and outcomes from, the phase 3 FeDeriCa trial in patients with HER2-positive early breast cancer.

Related Keywords

Maria Hafez ,Sidney Kimmel Medical College ,Thomas Jefferson University ,Clinical Breast Cancer Research ,D ,Federica Trial ,Patients With Her2 Positive Early Breast Cancer ,